Eubacterium

Some of the most protective bacteria in your colon carry this name. So do a few that track with worse outcomes. That is the first thing to know about a genus-level result: it blends species that point in opposite directions.

The best-studied species ferment fiber into butyrate. When those species run low, the pattern shows up in inflammatory bowel disease, psoriasis, ME/CFS, and ALS. This is a research marker with no validated normal range, which is why your own baseline and trend are worth more than one number.

What the Test Actually Counts

Eubacterium isn't a human molecule. The assay pulls DNA out of your stool and counts copies of bacterial genes, often a stretch of the 16S ribosomal RNA gene that differs between bacterial groups. What comes back is a measure of how much of this genus is present in what your gut shed, not a measure of anything your own cells made.

Three limits follow from that, and all of them matter when you read your own result. Stool captures the luminal community, while some published evidence comes from biopsies of the gut lining. A genus-level count also can't tell you which species is driving it, even though species inside this genus behave very differently from each other. And the naming itself has moved: the species with the most evidence behind it, Eubacterium rectale, was formally reclassified as Agathobacter rectalis, so depending on which reference database your lab uses, the single most important organism in this story may be reported outside the genus rather than inside your Eubacterium number.

Butyrate and the Colon Lining

These are strict anaerobes. Oxygen kills them, so they live mostly in your large intestine. They break down complex carbohydrates you can't digest and release short-chain fatty acids, mainly butyrate along with acetate and propionate. Butyrate is the primary fuel your colon cells burn, and it can also calm inflammatory signaling in the lining above them.

Eubacterium rectale, now formally Agathobacter rectalis although most published work still uses the older name, and Anaerobutyricum hallii, still called Eubacterium hallii in older papers, are two of the best-studied butyrate producers tied to this name. Other species do different jobs. Eubacterium coprostanoligenes converts cholesterol into a form you can't absorb, and Eubacterium eligens has been studied for how it uses plant compounds. One name, several unrelated trades.

Inflammatory Bowel Disease

This is the strongest and most repeatable finding attached to the genus. A systematic review of 48 studies found Eubacterium rectale lower in all ulcerative colitis studies that measured it. One small Crohn's disease fecal study found healthy controls carried roughly five to ten times more Eubacterium rectale and Faecalibacterium prausnitzii than people with Crohn's disease.

Severity tracks with it too. In people with ulcerative colitis followed over time with repeated biopsies, Eubacterium rectale counts in the gut lining moved inversely with both the clinical activity score and what the endoscopist saw: the sicker the colon, the fewer of these bacteria. Those measurements came from tissue rather than stool, so a stool number is a rougher proxy for the same biology.

If you have inflammatory bowel disease, this is the practical use. A stool panel won't diagnose a flare or replace calprotectin and endoscopy, but watching your fermentation community over a year of remission can show whether the part of your microbiome that makes your lining's fuel is recovering or staying flat.

Beyond the Gut

The same depletion pattern shows up in conditions that have nothing to do with the bowel. In 70 people with plaque psoriasis or psoriatic arthritis compared against 25 controls, Eubacterium rectale was markedly lower. In people with amyotrophic lateral sclerosis, 66 of them against 61 healthy controls, it was lower again, and the gap held after accounting for age, sex, and constipation.

In ME/CFS, a study of 197 people found reduced butyrate-producing capacity overall, with both Faecalibacterium prausnitzii and Eubacterium rectale reduced. Fatigue severity tracked most clearly with Faecalibacterium prausnitzii, not Eubacterium rectale. A cohort of 6,419 adults followed forward found that people with more butyrate producers overall were modestly less likely to develop pneumonia later, with about a tenth lower risk for each step up the range. That last finding is about the butyrate-producing group as a whole, not this genus measured on its own.

None of this means low Eubacterium causes any of those diseases. These are associations, and a thinned fermentation community can be downstream of illness itself, diet changes that come with being sick, and antibiotics.

When the Number Goes the Other Way

Read only the paragraphs above and you'd conclude more is always better. The evidence doesn't say that.

That fatty liver row is a minority signal, not a reversal of the field: across most fatty liver work, these butyrate producers thin out as fibrosis progresses, and the increase shows up only in particular subgroups. What it does establish is that the direction isn't fixed by the genus alone.

The split runs deeper than those three rows. Genetics-based analyses put the Eubacterium rectale group at about 60% lower odds of multiple myeloma while the Eubacterium ruminantium group carried about 70% higher odds, which is genetically predicted association rather than a measured cohort. In breast cancer chemotherapy, low baseline Eubacterium hallii group came with more severe neutropenia and liver enzyme elevation, while a broader Eubacterium signal came with more severe anemia. And in coronary heart disease, an unidentified Eubacterium was elevated alongside a branched fatty acid that comes from protein fermentation rather than fiber.

So this isn't a good-number, bad-number marker at the genus level. It's a shared surname over a family with different jobs, and a single count sums species that push opposite ways. Read your result as one input into a fermentation picture, next to butyrate itself and the other fiber-fermenting genera, rather than as a score that simply goes up or down.

Gum Disease and the Gut

Severe periodontitis can reshape the gut community, and this genus can be part of the signal. In an exploratory study of 44 people with different periodontal status, fecal Eubacterium biforme rose with how deep the pockets around the teeth measured, a modest link of about 0.34 on a scale where 1.0 would be a perfect match. The sample was small and the work exploratory, so treat this as a lead rather than a settled finding.

Treatment can move the wider gut profile back toward controls. In one matched clinical study, gut microbial profiles changed three months after mechanical periodontal therapy and looked closer to those of healthy controls. That study did not prove a clean Eubacterium-specific drop. A genetics-based analysis drawing on more than 800,000 people pointed the other way for one species, with the Eubacterium xylanophilum group appearing protective against bleeding gums, again as genetic inference rather than a measured stool result.

Why One Reading Isn't Enough

Stool is a messy specimen. A scoop from one part of an unhomogenized bowel movement can over- or under-sample particular bacteria, and different labs can call the same community differently because they use different primers, gene targets, and reference databases. The reclassification of Eubacterium rectale to Agathobacter rectalis is exactly the kind of database difference that can shift a genus count between labs without anything changing in your gut.

So build a line, not a dot. Get a baseline while you're eating normally, then compare later results from the same lab. The direction of travel across three samples is worth far more than any single one of them.

A retest has limits. The trials showing that diet or probiotics move these bacteria mostly measured the butyrate-producing group as a whole, or one species in gut lining tissue rather than stool. If your genus count rises after you add fiber, that's consistent with the evidence, not proof your supplement did it.

False Highs and False Lows

Four things distort a single reading often enough to matter.

• Sampling technique: a scoop from one spot of a formed stool isn't representative. Follow the kit's mixing instructions exactly, and collect at a consistent point in your usual routine.
• Recent gut infection: in 39 people with Entamoeba histolytica infection, Eubacterium dropped sharply alongside Bacteroides and other commensals. A sample taken during or shortly after any intestinal infection reads the infection, not your baseline.
• Antibiotics and acid suppressants: recent antibiotics can flatten the whole community for weeks to months. Proton pump inhibitors reshuffle it differently, pushing mouth bacteria into the gut rather than changing this genus directly, but the resulting community shift can still move the numbers around it.
• Lab-to-lab differences: different primers, gene targets, and naming databases give different counts on the same stool. Compare your result only against your own previous results from the same lab.

Building the Rest of the Picture

An odd result on its own is close to uninterpretable. Check it next to Faecalibacterium prausnitzii and Roseburia, the other major butyrate producers, plus stool butyrate itself and fecal calprotectin. Those five together give context a single genus can't.

Three patterns are worth separating. Low Eubacterium with low Faecalibacterium, low butyrate, and a normal calprotectin points at fermentation capacity rather than disease, and belongs in the diet-and-retest lane. Low commensals with a raised calprotectin and real symptoms, such as blood, urgency, weight loss, or night-time stools, is a gastroenterology referral and probably an endoscopy, not another microbiome panel. An isolated genus number that looks off while butyrate, calprotectin, and everything else reads normal and you feel fine is most likely sampling noise until a repeat says otherwise.

If your gums bleed when you brush and this pattern shows up together, see a periodontist. That's one place where treating something outside the gut has been shown to shift the gut community.